Valeant Pharmaceuticals International Inc. (TSE: VRX) is set to pay $236 million for Solta Medical Inc., a distributor of various skin care brands. 

Valeant—Canada’s largest drug maker and one of Mergers & Acquisitions’ “Seven Savvy Strategic Buyers”— says the deal would immediately add to earnings.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.